Table 2 Univariable analysis of patients’ 5-year overall survival
Variable | P | Hazard ratio(95% CI) |
|---|---|---|
Age (< 65/> 65) | 0.9971 | 1.0011 (0.5156–1.8782) |
Gender (female/male) | 0.6125 | 1.2410 (0.5036–2.6421) |
pT (pT1/pT2,3,4) | 0.0011* | 3.7983 (1.6271–11.083) |
pN(pN0/pN1,2,3) | 0.0002* | 4.9747 (1.9864–16.656) |
M (M0/M1) | 0.5615 | 1.5686 (0.2551–5.1250) |
pStage (pStageI,II/pStageIII,IV) | 0.0001* | 3.7464 (1.8595–8.3655) |
Tumor differentiationa (G1, G2/G3) | 0.5702 | 1.3259 (0.4539–3.1015) |
Lymphatic invasion (−/+) | 0.0260* | 2.3425 (1.0999–5.7744) |
Vessel invasion (−/+) | 0.0178* | 3.3192 (1.1995–13.757) |
Recist gradeb (PR, CR/SD, PD) | 0.0015* | 3.4976 (1.5642–9.3125) |
Histopathological tumor regression gradec (Grade0,1a/Grade1b,2) | 0.0432* | 0.4956 (0.2300–0.9795) |
post-NAC GR expression (Low/High) | 0.0479* | 1.8991 (1.0060–3.7409) |
post-NAC Sgk1 expression (Low/High) | 0.0054* | 2.5045 (1.3030–5.1191) |
post-NAC NDRG1expression (Low/High) | 0.0033* | 2.5632 (1.3716–4.8540) |